scispace - formally typeset
D

Domenico Marco Bonifati

Researcher at University of Padua

Publications -  29
Citations -  1366

Domenico Marco Bonifati is an academic researcher from University of Padua. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 23 publications receiving 1088 citations. Previous affiliations of Domenico Marco Bonifati include University of Brescia.

Papers
More filters
Journal ArticleDOI

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, +623 more
- 01 Dec 2017 - 
TL;DR: A phase 3, randomised, double-blind, placebo-controlled, multicentre study in 76 hospitals and specialised clinics across North America, Latin America, Europe, and Asia to assess the efficacy and safety of eculizumab in patients with refractory myasthenia gravis.
Journal ArticleDOI

Role of complement in neurodegeneration and neuroinflammation.

TL;DR: The role of complement-mediated inflammation in Alzheimer disease has drawn greater attention recently in view of new therapeutic advances made in the management of the disease, and recent vaccination and immunotherapeutic approaches are updated.
Journal ArticleDOI

Structural and functional anatomy of the globular domain of complement protein C1q.

TL;DR: The crystal structure of the gC1q, molecular modeling and protein engineering studies have combined to illustrate how modular organization, charge distribution and the spatial orientation of the heterotrimeric assembly offer versatility of ligand recognition to C1q.
Journal ArticleDOI

Innate Immunity and Neuroinflammation

TL;DR: How innate immune components can also contribute to neuroinflammation and neurodegeneration is discussed.
Journal ArticleDOI

Long-term cyclosporine treatment in a group of severe myasthenia gravis patients.

TL;DR: CsA treatment may be a valuable and cost effective treatment in severe MG and increased muscle strength and reduced corticosteroid dosage.